NO20080433L - Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene - Google Patents

Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene

Info

Publication number
NO20080433L
NO20080433L NO20080433A NO20080433A NO20080433L NO 20080433 L NO20080433 L NO 20080433L NO 20080433 A NO20080433 A NO 20080433A NO 20080433 A NO20080433 A NO 20080433A NO 20080433 L NO20080433 L NO 20080433L
Authority
NO
Norway
Prior art keywords
respiratory tract
administration
inflammatory conditions
active protein
conditions affecting
Prior art date
Application number
NO20080433A
Other languages
English (en)
Norwegian (no)
Inventor
Lars Otto Uttenthal
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Publication of NO20080433L publication Critical patent/NO20080433L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20080433A 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene NO20080433L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002773 WO2007012976A2 (fr) 2005-06-24 2006-06-23 Administration aux voies aeriennes de proteine c activee dans des condition inflammatoire affectant la voie respiratoire

Publications (1)

Publication Number Publication Date
NO20080433L true NO20080433L (no) 2008-03-19

Family

ID=37570814

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20080433A NO20080433L (no) 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene
NO20080434A NO20080434L (no) 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20080434A NO20080434L (no) 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien

Country Status (15)

Country Link
US (3) US8088728B2 (fr)
EP (3) EP1896059B1 (fr)
JP (3) JP2008543925A (fr)
KR (2) KR20080074085A (fr)
CN (2) CN101262879B (fr)
AU (2) AU2006260599A1 (fr)
BR (2) BRPI0613137A2 (fr)
CA (2) CA2612597C (fr)
DK (3) DK1898945T3 (fr)
HK (1) HK1114567A1 (fr)
IL (2) IL188220A0 (fr)
NO (2) NO20080433L (fr)
RU (2) RU2496515C2 (fr)
WO (3) WO2006136962A2 (fr)
ZA (2) ZA200800251B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101787B1 (fr) * 2006-12-11 2013-09-18 Drugrecure ApS Procédés de traitement de la mucoviscidose ou de la pneumonie avec infection bactérienne par administration pulmonaire de fosfomycine
RU2662564C2 (ru) 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
AU2014391082B2 (en) * 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring
CA3036553A1 (fr) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Procedes de traitement d'une maladie pulmonaire a l'aide de proteines inhibitrices d'inter-alpha

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
AU730133B2 (en) * 1996-11-08 2001-02-22 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
CA2278823A1 (fr) * 1997-01-29 1998-07-30 Joe M. Mccord Activateur du plasminogene utilise comme agent anti-inflammatoire
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
ES2234807T3 (es) * 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
ATE428445T1 (de) * 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
EP1385535A2 (fr) * 2001-05-02 2004-02-04 Novo Nordisk A/S Facteur vii modifie pour le traitement du syndrome de detresse respiratoire aigue
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
IL161407A0 (en) * 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US7189289B2 (en) * 2002-02-08 2007-03-13 Sk Corporation Cleaning agent and method for cleaning heater tubes
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
WO2004062689A1 (fr) * 2003-01-08 2004-07-29 Chiron Corporation Compositions aqueuses stabilisees de tfpi ou de ses variantes
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
WO2005042011A1 (fr) * 2003-11-04 2005-05-12 Novo Nordisk A/S Composition pharmaceutique contenant un polypeptide de proteine c et un regulateur de glucose sanguin
US8431535B2 (en) * 2004-09-10 2013-04-30 Hoiberg A/S Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
US8563511B2 (en) 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Also Published As

Publication number Publication date
KR20080071116A (ko) 2008-08-01
US8088728B2 (en) 2012-01-03
WO2007012976A3 (fr) 2007-07-12
CN101262879B (zh) 2013-04-10
EP1906994A2 (fr) 2008-04-09
HK1114567A1 (en) 2008-11-07
JP2008543925A (ja) 2008-12-04
CA2612597C (fr) 2015-03-31
CA2612646A1 (fr) 2006-12-28
NO20080434L (no) 2008-03-17
AU2006260599A1 (en) 2006-12-28
RU2008102655A (ru) 2009-07-27
KR20080074085A (ko) 2008-08-12
EP1898945B1 (fr) 2012-12-19
EP1906994B1 (fr) 2014-04-23
CA2612646C (fr) 2015-11-24
WO2006136963A2 (fr) 2006-12-28
WO2007012976A2 (fr) 2007-02-01
US20100160218A1 (en) 2010-06-24
ZA200800255B (en) 2009-04-29
JP2008543926A (ja) 2008-12-04
JP2013151510A (ja) 2013-08-08
US20100279925A1 (en) 2010-11-04
WO2006136963A3 (fr) 2007-07-12
CN101262879A (zh) 2008-09-10
BRPI0611710A2 (pt) 2011-12-20
EP1898945A2 (fr) 2008-03-19
CN101262880A (zh) 2008-09-10
ZA200800251B (en) 2009-04-29
RU2496515C2 (ru) 2013-10-27
DK1898945T3 (da) 2013-03-25
US20100297099A1 (en) 2010-11-25
DK1896059T3 (da) 2013-04-08
WO2006136962A2 (fr) 2006-12-28
AU2006273696A1 (en) 2007-02-01
BRPI0613137A2 (pt) 2010-12-21
RU2008102656A (ru) 2009-07-27
IL188220A0 (en) 2008-03-20
RU2496516C2 (ru) 2013-10-27
AU2006273696B2 (en) 2012-08-30
EP1896059A2 (fr) 2008-03-12
CA2612597A1 (fr) 2007-02-01
WO2006136962A3 (fr) 2007-07-12
IL188221A0 (en) 2008-03-20
DK1906994T3 (da) 2014-07-21
EP1896059B1 (fr) 2012-12-19

Similar Documents

Publication Publication Date Title
Matthay et al. The acute respiratory distress syndrome
NO20080433L (no) Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene
NO20075077L (no) Fremgangsmate for a forbedre laering og hukommelse i pattedyr
NO20065232L (no) 8-(2-hydroksyfenoksy)oktyldietanolamin og salter derav for avlevering av aktive forbindelser
Wösten-van Asperen et al. ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin
WO2015016761A3 (fr) Cellules souches mésenchymateuses dans le traitement de maladies inflammatoires pulmonaires
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
NO20072466L (no) Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister
ATE516285T1 (de) Dihydropyridinonderivate
Stolarczyk et al. The EGFR‐ADAM17 axis in chronic obstructive pulmonary disease and cystic fibrosis lung pathology
DK1874341T3 (da) Erythrocytter, der indeholder arginin deiminase
EA201290374A1 (ru) Аэрозольная композиция для copd
ATE525394T1 (de) Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung
Pilecki et al. Surfactant protein D deficiency aggravates cigarette smoke-induced lung inflammation by upregulation of ceramide synthesis
DE602007001467D1 (de) Therapeutische Zubereitung von hochreinem FVIIa und Verfahren zu dessen Gewinnung
Lau et al. Enhanced fibrinolysis protects against lung ischemia–reperfusion injury
ATE402190T1 (de) Surfactant protein d zur vorbeugung und diagnose des lungenemphysems
Ge et al. Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients
WO2007110698A3 (fr) Méthodes destinées à inhiber la carcinogenèse et/ou la métastase chez un individu au moyen de ligands et d'inhibiteurs de c-met endogènes
JP2009520696A5 (fr)
NO20054556L (no) Amylinaggregeringsinhibitorer og anvendelse derav
Bei-ke et al. Correlation between activated protein C level and coagulation function and prognosis in patients with traumatic liver injury
Chen Dabigatran etexilate overdose
Eapen et al. M1 And M2 Macrophage Populations In The Airways Of Smokers And COPD Patients: Insights From Both Airway Tissue And Lumen
Stampfli et al. Prostaglandin E2 Attenuates Cigarette Smoke-Induced Cellular Inflammation In A Socs3-Independent Manner